Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Cash (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Cash for 3 consecutive years, with -$28.9 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 33.99% to -$28.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.4 million through Dec 2025, up 77.36% year-over-year, with the annual reading at -$28.4 million for FY2025, 77.36% up from the prior year.
  • Change in Cash for Q4 2025 was -$28.9 million at Inhibrx Biosciences, up from -$33.5 million in the prior quarter.
  • The five-year high for Change in Cash was $144.8 million in Q3 2023, with the low at -$59.4 million in Q4 2023.
  • Average Change in Cash over 3 years is -$6.8 million, with a median of -$29.4 million recorded in 2025.
  • The sharpest move saw Change in Cash plummeted 121.08% in 2024, then skyrocketed 351.26% in 2025.
  • Over 3 years, Change in Cash stood at -$59.4 million in 2023, then increased by 26.37% to -$43.7 million in 2024, then skyrocketed by 33.99% to -$28.9 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$28.9 million, -$33.5 million, and -$30.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.